Cargando…

Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA

Detalles Bibliográficos
Autores principales: Hunt, Barnaby, Mocarski, Michelle, Valentine, William J., Langer, Jakob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487865/
https://www.ncbi.nlm.nih.gov/pubmed/28523624
http://dx.doi.org/10.1007/s12325-017-0543-6
_version_ 1783246535583072256
author Hunt, Barnaby
Mocarski, Michelle
Valentine, William J.
Langer, Jakob
author_facet Hunt, Barnaby
Mocarski, Michelle
Valentine, William J.
Langer, Jakob
author_sort Hunt, Barnaby
collection PubMed
description
format Online
Article
Text
id pubmed-5487865
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-54878652017-07-03 Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA Hunt, Barnaby Mocarski, Michelle Valentine, William J. Langer, Jakob Adv Ther Erratum Springer Healthcare 2017-05-18 2017 /pmc/articles/PMC5487865/ /pubmed/28523624 http://dx.doi.org/10.1007/s12325-017-0543-6 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Erratum
Hunt, Barnaby
Mocarski, Michelle
Valentine, William J.
Langer, Jakob
Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
title Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
title_full Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
title_fullStr Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
title_full_unstemmed Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
title_short Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
title_sort erratum to: evaluation of the short-term cost-effectiveness of ideglira versus continued up-titration of insulin glargine u100 in patients with type 2 diabetes in the usa
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487865/
https://www.ncbi.nlm.nih.gov/pubmed/28523624
http://dx.doi.org/10.1007/s12325-017-0543-6
work_keys_str_mv AT huntbarnaby erratumtoevaluationoftheshorttermcosteffectivenessofidegliraversuscontinueduptitrationofinsulinglargineu100inpatientswithtype2diabetesintheusa
AT mocarskimichelle erratumtoevaluationoftheshorttermcosteffectivenessofidegliraversuscontinueduptitrationofinsulinglargineu100inpatientswithtype2diabetesintheusa
AT valentinewilliamj erratumtoevaluationoftheshorttermcosteffectivenessofidegliraversuscontinueduptitrationofinsulinglargineu100inpatientswithtype2diabetesintheusa
AT langerjakob erratumtoevaluationoftheshorttermcosteffectivenessofidegliraversuscontinueduptitrationofinsulinglargineu100inpatientswithtype2diabetesintheusa